View Older Stories View More Recent Stories

Apr 13, 2020 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2020 Financial Results on April 30, 2020
Apr 8, 2020 08:00AM Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference
Apr 2, 2020 08:06AM Seattle Genetics (SGEN) Announces Potential Accelerated Approval Pathway in U.S. for PADCEV in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Apr 2, 2020 08:00AM Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advan
Mar 10, 2020 08:00AM Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference
Mar 2, 2020 08:00AM Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
Feb 26, 2020 08:00AM Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference
Feb 19, 2020 08:28AM Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Feb 19, 2020 08:17AM Seattle Genetics (SGEN), Astellas Pharma Granted FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab
Feb 19, 2020 08:12AM Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Feb 13, 2020 08:01AM Seattle Genetics (SGEN) Announces FDA Filing Acceptance for Priority Review of Tucatinib NDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Feb 13, 2020 08:00AM Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Feb 11, 2020 08:00AM Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treat
Feb 10, 2020 05:02PM Seattle Genetics (SGEN) and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV for Advanced Bladder Cancer
Feb 10, 2020 05:00PM Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treat
Feb 6, 2020 04:02PM Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
Jan 31, 2020 08:05AM Seattle Genetics (SGEN) Announces EMA Validates its MAA for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Jan 31, 2020 08:00AM EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Jan 21, 2020 08:30AM Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020
Jan 21, 2020 08:01AM Seattle Genetics (SGEN) will receive milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy
Jan 21, 2020 08:00AM Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin)
Jan 6, 2020 08:00AM Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Dec 23, 2019 08:04AM Seattle Genetics (SGEN) Announces Submission of Tucatinib NDA to FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Dec 23, 2019 08:00AM Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Dec 19, 2019 06:27AM FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' (SGEN) PADCEV for People with Locally Advanced or Metastatic Urothelial Cancer
Dec 18, 2019 07:49PM FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder
Dec 18, 2019 06:42PM Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval
Dec 18, 2019 06:36PM FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bla
Dec 18, 2019 08:02AM Seattle Genetics (SGEN) Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Dec 18, 2019 08:00AM Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Dec 13, 2019 08:05PM Annual Changes to the NASDAQ-100 Index
Dec 11, 2019 09:55AM Seattle Genetics (SGEN) Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at SABCS and Published in NEJM
Dec 11, 2019 09:54AM Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of
Dec 9, 2019 10:03AM Seattle Genetics (SGEN), Takeda (TAK) Announce Additional Analyses of ADCETRIS ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at ASH
Dec 9, 2019 10:00AM Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Dec 9, 2019 10:00AM Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Dec 7, 2019 02:00PM Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Dec 2, 2019 08:04AM Seattle Genetics (SGEN), Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA in Patients with Metastatic Urothelial Cancer
Dec 2, 2019 08:00AM Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
Dec 2, 2019 08:00AM Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
Nov 25, 2019 08:04AM Seattle Genetics (SGEN) Reports Health Canada Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy
Nov 25, 2019 08:00AM Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Nov 12, 2019 05:17PM Seattle Genetics (SGEN) Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership
Nov 12, 2019 05:15PM Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership
Nov 7, 2019 08:17AM Seattle Genetics (SGEN) Announces Multiple ADCETRIS Presentations at ASH
Nov 7, 2019 08:00AM Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting
Nov 5, 2019 08:15AM BeiGene (BGNE). Seattle Genetics (SGEN) Report Global License Agreement for Advanced Preclinical Product Candidate
Nov 5, 2019 08:00AM Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate
Nov 4, 2019 11:51PM Seattle Genetics Responds to Daiichi Sankyo’s Complaint for Declaratory Judgment
Nov 4, 2019 08:00AM Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference
View More Recent Stories View Older Stories